Investors question green tint of Teva's $5bn sustainability bond | Financial Times
Teva completes $40b purchase of Allergan generics arm | The Times of Israel
Teva Pays $420 Million to End Generic-Drug Securities Suit (1)
Why Teva Pharmaceuticals Has Significant Upside (NYSE:TEVA) | Seeking Alpha
Earnings Preview: It's a mixed bag for Teva Pharma in Q3 | AlphaStreet
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
Teva New Case Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Teva Pharmaceutical Industries Limited To Contact The Firm
Teva Pharmaceutical Industries. Information about the issuer. (LEI 549300BAFGM4RC74ZJ94, SWIFT TEVPILITXXX). News and credit ratings. Tables with accounting and financial reports.
How Teva Beat the Big Pharma Curse to Win 2018 | Barron's
Teva Bonds: 8.8% Yield To Maturity Understates Upside | Nasdaq
Hedge Funds Are Dipping Their Toes Into Teva Pharmaceutical Industries (TEVA )
Teva Stock Skids As First-Quarter Sales Decline — Again | Investor's Business Daily
Investors Are Overpaying for Teva's Turnaround - WSJ
Teva ponies up $420M to settle with investors who said company hid price-fixing scheme | Fierce Pharma
Is A Fall Imminent For Teva Stock After Its Recent Rally?
Jewish Values Investors JLens Target Israeli Company – The Forward
Teva: This One Is Difficult (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceutical loses another CEO, leaving investors to guess what's next
Teva Stock Investors Should Keep Their Hands on the Pause Button | InvestorPlace
Teva Pharmaceutical
Teva Investor Relations by Teva Pharmaceuticals USA, Inc.
Teva Pharmaceuticals - Wikipedia
